Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Deal Volume On The Rise Heading Into J.P. Morgan

Executive Summary

Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.

You may also be interested in...



Finance Watch: DRI Healthcare’s Canadian IPO Enables More Royalty Deals

Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.

Argenx Advances Efgartigimod Into China With Zai Lab Pact

Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.

AmerisourceBergen Strikes $6.5bn Deal For Alliance

AmerisourceBergen has struck a $6.5bn deal to acquire the majority of the Alliance Healthcare businesseses from Walgreens Boots Alliance, giving it access to Alliance’s generics assets in Europe.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel